Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia and Schizoaffective Disorder
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox.
- Trial name
- NCT00347425
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- 122 sites in United States, Argentina and 7 more
- Volunteers
- 286 people
- Sponsor
- Solvay Pharmaceuticals
Schizo-Affective Type of Psychosis, Schizophrenia
Ocrelizumab for Psychosis by Autoimmunity
Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies.
- Trial name
- OPA (NCT03971487)
- Testing
- Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Borderline Personality Disorder, BPD
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Social cognition impairment is critical to the pathology and morbidity of a number of psychiatric disorders, including the schizophrenia spectrum, the autism spectrum and the personality disorders, thus representing a dimension…
- Conditions
- Borderline Personality Disorder, BPD, Schizotypal Personality Disorder, SPD
- Trial name
- NCT02149823
- Testing
- Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU)
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Maria de las Mercedes Perez Rodriguez
Schizophrenia Spectrum Disorders, Schizophrenia
Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis
This study is to evaluate the safety and efficacy of Virtual Reality Mindfulness in Patients With Psychosis.
- Conditions
- Schizophrenia Spectrum Disorders, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT05784948
- Testing
- Virtual Reality Mindfulness Treatment, Experience relaxing scenery and music
- Where
- South Korea
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophreniform Disorder, Bipolar I Disorder
Prevention of Weight Gain in Early Psychoses
The purpose of this study is to determine whether individuals with psychotic spectrum disorders ( Schizophrenia, Schizoaffective disorder,Schizophreniform Disorder, Bipolar Disorder (Type I),Bipolar Disorder (Type II),Major…
- Conditions
- Schizophreniform Disorder, Bipolar I Disorder, Bipolar II Disorder, Major Depressive Disorder
- Trial name
- NCT01075295
- Testing
- Behavioural Intervention for the Prevention of Weight Gain, TAU
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Agitation
- Trial name
- NCT00797277
- Testing
- IM olanzapine, IM haloperidol plus lorazepam
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Schizoaffective Disorder
Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients
In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.
- Trial name
- NCT01043250
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Samsung Medical Center
Schizophrenia, Schizoaffective Disorder
Cognitive Adaption Training-Effectiveness in Real-world Settings and Mechanism of Action (CAT-EM)
The investigators propose a cluster randomized effectiveness trial comparing Cognitive Adaptation Training (CAT; a psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology…
- Trial name
- CAT-EM (NCT03829280)
- Testing
- Cognitive Adaptation Training, Community Treatment
- Where
- 8 sites in United States
- Volunteers
- 205 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Schizoaffective Disorder
Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia
To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.
- Trial name
- NCT00283179
- Testing
- Aripiprazole, Risperidone
- Where
- Taiwan
- Volunteers
- 83 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Schizophrenia, Schizoaffective Disorder
Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia
This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia.
- Trial name
- NCT00406718
- Testing
- Med-eMonitor, PharmCAT, Treatment as Usual
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Treatment-resistant Schizophrenia
Neural Biomarkers of Clozapine Response
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown.
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03076346
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Research of Anatomo-functional Biomarkers in Schizophrenia
To objectify UR biomarkers, we propose a longitudinal follow-up of resistant patients with schizophrenia, starting before the onset of clozapine and including a multimodal brain imaging assessment (T1 and T2 weighted sequences…
- Trial name
- CLOZAREST (NCT03996122)
- Testing
- fMRI
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Caen
Schizophrenia Relapse, Schizophrenia
Feasibility and Acceptability of a Smartphone App to Assess Early Warning Signs of Psychosis Relapse
About 1 in 100 people will experience an episode of psychosis. Some people will only experience one 'psychotic episode' and about a quarter of people make a full recovery.
- Conditions
- Schizophrenia Relapse, Schizophrenia, Schizo Affective Disorder, Psychotic Disorders
- Trial name
- ExPRESS:2 (NCT03558529)
- Volunteers
- 27 people
- Sponsor
- Manchester Academic Health Science Centre
Schizophrenia, Schizoaffective Disorder
Adherence and Quality of Life in People With Schizophrenia and Schizoaffective Disorder
It is the goal of this study adherence and quality of life in a population of people suffering from schizophrenia or schizoaffective disorder and to analyze if these factors are influenced by treatment, support, social services…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Quality of Life
- Trial name
- NCT01769014
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Psychiatrische Dienste Graubuenden
Schizophrenia, Schizo Affective Disorder
Acetazolamide for Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
- Trial name
- APTS (NCT04887792)
- Testing
- Acetazolamide
- Where
- 2 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
Schizophrenia, Schizoaffective Disorder
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
- Trial name
- NCT00139906
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Efficacy of Pregnenolone in Patients With Schizophrenia
Four-month trial of pregnenolone or placebo, as an additional medication, to treat negative symptoms and cognitive decline in schizophrenia.
- Trial name
- NCT00615511
- Testing
- pregnenolone
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Weill Medical College of Cornell University
Schizophrenia, Schizoaffective Disorder
Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia
The purpose of this study is to evaluate the safety of risperidone treatment in patients who are overweight and/or obese.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00511628
- Testing
- Risperidone
- Volunteers
- 1,717 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Bipolar Disorder
Mobile Self-Tracking of Mental Health
Serious mental illnesses require years of monitoring and adjustments in treatment. Stress, substance abuse or reduced medication adherence cause rapid worsening of symptoms, with consequences that include job loss, homelessness…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Post-traumatic Stress Disorder
- Trial name
- NCT05023252
- Testing
- mobile application
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- VA Office of Research and Development